Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers
J Am Acad Dermatol 2025;93:104–14 doi: 10.1016/j.jaad.2025.03.016
In this nationwide study of Swedish PsO and PsA patients treated with ustekinumab, etanercept, adalimumab, or secukinumab, spanning more than 10 years, the overall risk of MACE was low across treatment groups. There was no meaningful difference in risk of MACE between ustekinumab and the other treatments.
Banefelt et al. estimated and compared the risk of MACE in patients with PsO and PsA initiating treatment with ustekinumab relative to patients initiating treatment with adalimumab, etanercept, and secukinumab in routine clinical practice.
Keywords:
